AMA-backed Health2047 rolls out new cybersecurity platform

Health2047, a venture studio supported by the American Medical Association, announced the launch of HEAL Security, a cybersecurity platform dedicated to the healthcare sector. The company has raised $4.6 million in pre-seed funding, with Health2047 contributing $2.3 million.

HEAL Security's platform is specifically designed to address the particular cybersecurity challenges faced by healthcare providers. The company said the tool offers real-time, tailored threat intelligence and risk assessment for protecting patient data amid a rise in cyber threats targeting healthcare systems, which are a top target due to the large amount of valuable patient information their EHRs possess.

"The sector has experienced nearly $7.8 billion in losses due to breaches since 2016,” said Lawrence K. Cohen, CEO of Health2047, in a statement. “The threat is so pervasive that some institutions are having to revert to paper records, setting back healthcare's digital evolution and making it harder for physicians to perform their duties.”

The main aim of the platform’s approach is to streamline cybersecurity management. "Our platform synthesizes, aggregates and contextualizes data, offering clarity and actionable strategies,” said Charles Aunger, founder and CEO of HEAL Security.

Health2047’s healthcare-focused lineup of companies also includes Evidium and Zing Health.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.